AU2020337883B2 - Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors - Google Patents

Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors

Info

Publication number
AU2020337883B2
AU2020337883B2 AU2020337883A AU2020337883A AU2020337883B2 AU 2020337883 B2 AU2020337883 B2 AU 2020337883B2 AU 2020337883 A AU2020337883 A AU 2020337883A AU 2020337883 A AU2020337883 A AU 2020337883A AU 2020337883 B2 AU2020337883 B2 AU 2020337883B2
Authority
AU
Australia
Prior art keywords
indazol
dihydrothieno
cyclopenta
methyl
methy1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020337883A
Other languages
English (en)
Other versions
AU2020337883A1 (en
Inventor
Yi-Mei CHANG
Yuan-Ting Cho
Hung-Jyun HUANG
Chu-Bin Liao
Yu-Chih PAN
Shao-Zheng Peng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
Original Assignee
Development Center for Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology
Publication of AU2020337883A1 publication Critical patent/AU2020337883A1/en
Application granted granted Critical
Publication of AU2020337883B2 publication Critical patent/AU2020337883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020337883A 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors Active AU2020337883B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891097P 2019-08-23 2019-08-23
US62/891,097 2019-08-23
PCT/US2020/047552 WO2021041276A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2020337883A1 AU2020337883A1 (en) 2022-03-24
AU2020337883B2 true AU2020337883B2 (en) 2025-08-28

Family

ID=74685735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020337883A Active AU2020337883B2 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors

Country Status (11)

Country Link
US (1) US12448394B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017853A4 (cg-RX-API-DMAC7.html)
JP (1) JP7651557B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220051365A (cg-RX-API-DMAC7.html)
CN (1) CN114502553B (cg-RX-API-DMAC7.html)
AU (1) AU2020337883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151821A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002062A (cg-RX-API-DMAC7.html)
TW (1) TWI759829B (cg-RX-API-DMAC7.html)
WO (1) WO2021041276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278010A (zh) * 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274255A1 (en) * 2012-04-12 2013-10-17 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
RU2425677C2 (ru) 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
BRPI0618011A2 (pt) * 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
CA2780892C (en) * 2009-11-13 2017-02-14 Genosco Kinase inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
WO2013142382A1 (en) * 2012-03-22 2013-09-26 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN119792569A (zh) 2018-01-10 2025-04-11 财团法人生物技术开发中心 抗体protac偶联物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274255A1 (en) * 2012-04-12 2013-10-17 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof

Also Published As

Publication number Publication date
CN114502553A (zh) 2022-05-13
WO2021041276A1 (en) 2021-03-04
EP4017853A4 (en) 2023-08-30
US12448394B2 (en) 2025-10-21
MX2022002062A (es) 2022-04-25
TWI759829B (zh) 2022-04-01
AU2020337883A1 (en) 2022-03-24
CN114502553B (zh) 2024-07-26
TW202115087A (zh) 2021-04-16
EP4017853A1 (en) 2022-06-29
CA3151821A1 (en) 2021-03-04
US20220289759A1 (en) 2022-09-15
KR20220051365A (ko) 2022-04-26
JP7651557B2 (ja) 2025-03-26
BR112022003383A2 (pt) 2022-05-17
JP2022545019A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
CN107922431B (zh) Hpk1抑制剂及其使用方法
JP5871896B2 (ja) B−rafキナーゼインヒビター
JP2025118762A (ja) ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
JP2024102236A (ja) Prmt5阻害剤
CN117062818A (zh) 新型sos1抑制剂及其制备方法和应用
JP5863058B2 (ja) 1H−イミダゾ[4,5−c]キノリン
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
TW202521536A (zh) Cdk抑制劑
JP2021514373A (ja) Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体
EP2646432A1 (en) Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
CN111072645B (zh) 作为TGF-βR1抑制剂的化合物及其应用
AU2017342928A1 (en) Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
US12448394B2 (en) Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors
CA2946990A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
AU2024284667A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
HK40057478B (en) Hpk1 inhibitors and methods of using same
WO2025113625A1 (zh) 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用
WO2026102147A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
CA3211149A1 (en) Pharmaceutical compound
HK40057478A (en) Hpk1 inhibitors and methods of using same
HK40043317A (en) COMPOUND AS TGF-β R1 INHIBITOR AND APPLICATION THEREOF

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)